Mercaptoalbumin Is Associated with Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting

Antioxidants (Basel)

29 Aprile Apr 2022 7 months ago
  • Brioschi M, Gianazza E, Andreini D, Mushtaq S, Cavallotti L, Tedesco CC, Colombo GI, Pepi M, Polvani G, Banfi C.

Coronary artery bypass graft (CABG) surgery still represents the gold standard for patients with complex multivessel coronary artery disease. However, graft occlusion still occurs in a significant proportion of CABG conduits, and oxidative stress is currently considered to be a potential contributor. Human serum albumin (HSA) represents the main antioxidant in plasma through its reduced amino acid Cys34, which can efficiently scavenge several oxidants. In a nested case-control study including 36 patients with occluded grafts and 38 age- and sex-matched patients without occlusion, we assessed the levels of the native mercaptoalbumin (HSA-SH) and oxidized thiolated form of albumin (Thio-HSA) in relation with graft occlusion within 5 years after CABG. We found that the plasma level of preoperative HSA-SH was significantly lower in patients with occluded graft at 5 years follow-up than in patients with graft patency. Furthermore, low HSA-SH remained independently associated with graft occlusion even after adjusting for preoperative D-dimer, a well-known marker of activated coagulation recently found to be associated with graft occlusion. In conclusion, the preoperative level of HSA-SH is independently associated with graft occlusion in CABG and represents a measurable and potentially druggable predictor.

Reference: Mercaptoalbumin Is Associated with Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting. Brioschi M, Gianazza E, Andreini D, Mushtaq S, Cavallotti L, Veglia F, Tedesco CC, Colombo GI, Pepi M, Polvani G, Tremoli E, Parolari A, Banfi C. Antioxidants (Basel). 2022 Apr 2;11(4):702.

Go to PubMed